Management of onychomycoses

Drugs

Volumn 58, Issue 2, 1999, Pages 283-296

  Niewerth, Markus ^a   Korting, Hans C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTACID AGENT; ANTIFUNGAL AGENT; BIFONAZOLE; CARBAMAZEPINE; CICLOPIROX; CLOTRIMAZOLE; COUMARIN; CYCLOSPORIN; DIDANOSINE; DIGOXIN; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; HISTAMINE H2 RECEPTOR ANTAGONIST; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; NIFEDIPINE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; TERBINAFINE; TERFENADINE; TIOCONAZOLE; UREA;

CLINICAL FEATURE; CLINICAL TRIAL; DERMATOPHYTE; DRUG BLOOD LEVEL; DRUG COST; DRUG FATALITY; DRUG METABOLISM; ERYTHEMA MULTIFORME; FOOD DRUG INTERACTION; FUNGUS GROWTH; HEADACHE; HEPATITIS; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; STEVENS JOHNSON SYNDROME; STOMACH PAIN; TASTE DISORDER; TOPICAL DRUG ADMINISTRATION; TOXIC EPIDERMAL NECROLYSIS; VOMITING;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DRUG INTERACTIONS; HUMANS; ONYCHOMYCOSIS; QUALITY OF LIFE;

ARTHRODERMATACEAE; FUNGI; TINEA;

EID: 0032799134     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958020-00005     Document Type: Review

References (127)

1. 1. Haneke E. Therapie der Nagelmykosen. Hautarzt 1993; 44: 335-46
2. 2. Williams HC. The epidemiology of onychomycosis in Britain. Br J Dermatol 1993; 129: 101-9
3. 3. Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994; 31: S21-5
4. 4. Baran R, Badillet G. Primary onycholysis of the big toenails: a review of 113 cases. Br J Dermatol 1982; 106: 529-34
5. 5. Symonds JM, O'Dell CA. Candida nail bed infection and cosmetic acrylic extensions - potential source of hospital infection? J Hospital Infect 1993; 23: 243-4
6. 6. Lubeck DP, Patrick DL, McNulty P, et al. Quality of life of persons with onychomycosis. Quality Life Res 1993; 2: 341-8
7. 7. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130 Suppl. 43: 15
8. 8. Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997; 22: 87-9
9. 9. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997; 36: 754-6
10. 10. Zaias N. Clinical manifestations of onychomycoses. Clin Exp Dermatol 1992; 17 Suppl. 1: 6-7
11. 11. Baran R, Hay RJ, Tosti A, et al. A new classification of onychomycosis. Br J Dermatol 1998; 139: 567-71
12. 12. Leyden JL. Tinea pedis: pathophysiology and treatment. J Am Acad Dermatol 1994; 31: S31-3
13. 13. Evans EGV. Nail dermatophytosis: the nature and scale of the problem. J Dermatol Treatment 1990; 1 Suppl. 2: 47-8
14. 14. Hancke E. Fungal infections of the nail. Semin Dermatol 1991; 10: 41-53
15. 15. Midgley G, Moore MK, Cook JC, et al. Mycology and nail disorders. J Am Acad Dermatol 1994; 31: S68-74
16. 16. Elewski BE, Greer DL. Hendersonula toruloidea and Scytalidium hyalinum. Arch Dermatol 1991; 127: 1041-4
17. 17. Baran R, Tosti A, Piraccini BM. Uncommon clinical patterns of Fusarium nail infection: report of three cases. Br J Dermatol 1997; 136: 424-7
18. 18. Ellis DH, Watson AB, Marley J, et al. Non-dermatophytes in onychomycosis of the toenails. Br J Dermatol 1997; 136: 490-3
19. 19. Gupta AK, Sibbald RG, Lynde CW et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997; 36: 395-402
20. 20. Zienicke HC, Korting HC, Lukacs A, et al. Dermatophytosis in children and adolescents: epidemiology, clinical, and microbiological aspects changing with age. J Dermatol (Tokyo) 1991; 18: 438-46
21. 21. Korting HC, Schäfer-Korting M, Zienicke H, et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993; 37: 2064-8
22. 22. Dompmartin D, Dompmartin A, Deluol AM, et al. Onychomycosis and AIDS: clinical and laboratory findings in 63 patients. Int J Dermatol 1990; 29: 337-9
23. 23. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11: 415-29
24. 24. Blecher P, Korting HC. A new combined diagnostic approach to clinically and microscopically suspected onychomycosis unproven by culture. Mycoses 1993; 36: 312-4
25. 25. Clayton YM. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol 1992; 17 Suppl. 1: 37-40
26. 26. Haneke E. Nail biopsies in onychomycosis. Mycoses 1985; 28: 473-80
27. 27. Suarez SM, Silvers DN, Scher RK, et al. Histologic evaluation of nail clippings for diagnosing onychomycosis. Arch Dermatol 1991; 127: 1517-9
28. 28. Meinhof W. Isolierung und Identifizierung von Dermatophyten. Zbl Bakt 1990; 273: 229-45
29. 29. Bastert J, Korting HC. Diagnostische Methoden zur Speziesspezifischen Differenzierung unterschiedlicher Dermatophyten. Dtsch Med Wschr 1998; 123: 499-503
30. 30. Baden HP. Treatment of distal onychomycosis with avulsion and topical antifungal agents under occlusion. Arch Dermatol 1994; 130: 558-9
31. 31. Cohen PR, Scher RK. Topical and surgical treatment of onychomycosis. J Am Acad Dermatol 1994; 31; S74-7
32. 32. Baran R, Hay RJ. Partial surgical avulsion of the nail in onychomycosis. Clin Exp Dermatol 1985; 10: 413-8
33. 33. Stettendorf S. Topical treatment of onychomycoses with bifonazole-urea ointment. In: Nolting S, Korting HC, editors. Onychomycoses. Berlin, Heidelberg: Springer, 1990: 102-8
34. 34. Abeck D, Gruseck E, Korting HC, et al. Onychomykose: Epidemiologie, Pathogenese, Klinik, Mikrobiologie und Therapie. Dtsch Ärztebl 1996; 93: A-2027-32
35. 35. Baran R, De Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol (Stockh) 1996; 76: 82-3
36. 36. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-33
37. 37. Schäfer-Korting M, Korting HC, Mutschler E. Human plasma and skin blister fluid levels of griseofulvin after its repeated administration. Eur J Clin Pharmacol 1985; 29: 351-4
38. 38. Warnock DW. New pharmacological concepts in antimycotic treatment. J Eur Acad Dermatol Venereol 1993; 2 Suppl. 1: S19-25
39. 39. Korting HC, Schäfer-Korting M. Is tinea unguium still widely incurable? Arch Dermatol 1992; 128: 243-8
40. 40. Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996; 51: 585-620
41. 41. Korting HC, Ollert M, Abeck D. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206-8
42. 42. Schäfer-Korting M, Korting HC, Lukacs A, et al. Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. J Am Acad Dermatol 1990; 22: 211-5
43. 43 Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-8
44. 44. Willemsen M, De Doncker P, Willems J. Post-treatment itraconazole levels in nail. New implications for the treatment of onychomycosis. J Am Acad Dermatol 1992; 26: 731-5
45. 45. Heykants J, Van Peer A, Van de Velde V. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32: 67-87
46. 46. Grant SM, Clissold SP. Itraconazole.: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-44
47. 47. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-84
48. 48. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14: 120-3
49. 49. Nolting S. Bräutigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994; 130 Suppl. 43: 16-21
50. 50. Niewerth M, Splancmann V, Korting HC, et al. Antimicrobial susceptibility testing of dermatophytes - comparison of the agar macrodilution and broth microdilution tests. Chemotherapy (Basel) 1998; 44: 31-5
51. 51. Schatz F, Bräutigam M, Dobrowolowski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20: 377-83
52. 52. Finlay AY, Lever L, Thomas R, et al. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990; 1 Suppl. 2: 51-3
53. 53. Nedelman JR, Gibiansky E, Robbins BA, et al. Pharmacokinetics and pharmacodynamics of multi-dose terbinafine. J Clin Pharmacol 1996; 36: 452-61
54. 54. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992; 304: 1151-4
55. 55. Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992; 128: 909-10
56. 56. Smith SW, Sealy DP, Schneider E, et al. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J 1995; 88: 1217-20
57. 57. Grant SM, Clissold SP, Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1990; 39: 877-916
58. 58. Wildfeuer A, Faergemann J, Laufen H, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994; 37: 127-30
59. 59. Wildfeuer A, Seidl HP. The in vitro activity of fluconazole against fungi involved in dermal infections. Mycoses 1994; 37: 447-9
60. 60. Faergemann J, Laufen H. Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toenails with fluconazole 150 mg once weekly. Acta Derm Venereol (Stockh) 1996; 76: 219-21
61. 61. Suringa DW. Treatment of superficial onychomycosis with topically applied glutaraldehyde. Arch Dermatol 1970; 102: 163-76
62. 62. White MI, Clayton YM. The treatment of fungus and yeast infections of nails by the method of 'chemical removal'. Clin Exp Dermatol 1982; 7: 273-6
63. 63. Hay RJ, Roberts DT, Doherty VR, et al. The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 1988; 13: 164-7
64. 64. Faergemann J, Swanbeck G. Treatment of onychomycosis with a propylene glycol-urea-lactic acid solution. Mycoses 1988; 32: 536-40
65. 65. Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 1987; 12: 175-7
66. 66. Haria M, Bryson HM. Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycoses and other superficial fungal infections. Drugs 1995; 49: 103-20
67. 67. Nolting S, Seebacher C. Ciclopiroxolamin, Wegweiser topischer Mykose-Therapie. Frankfurt, Jena: Universitätsverlag Jena, 1993
68. 68. Pharmaceutical Research Associates. Ciclopirox nail lacquer 8%: integrated summary of efficacy. Internal Report 1998
69. 69. Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992; 17 Suppl. 1: 44-9
70. 70. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 17 Suppl 1: 41-3
71. 71. Korting HC, Blecher P, Stallmann D, et al. Dermatophytes on the feet of HIV-infected patients: frequency, species distribution, localisation and antimicrobial susceptibility. Mycoses 1993; 36: 271-4
72. 72. Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750-3
73. 73. Hofmann H, Bräutigam M, Weidinger G. Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919-22
74. 74. Haneke C, Tausch I, Bräutigam M, et al. Short duration treatment of fingernail dermatophylosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72-7
75. 75. Goodfield MJD. Short duration therapy with terbinafine for dermatophyte onychomycosis: a multicenter trial. Br J Dermatol 1992; 126 Suppl. 39: 33-5
76. 76. Watson A, Marley J, Ellis D, et al. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995; 33: 775-9
77. 77. Svejgaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytosis. Acta Derm Venereol (Stockh) 1997; 77: 66-9
78. 78. Goodfield MJD. Clinical results with terbinafine in onychomycosis. J Dermatol Treatment 1990; 1 Suppl. 2: 55-7
79. 79. Tausch I, Bräutigam M, Weidinger G, et al. Evaluations of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. Br J Dermatol 1997; 136: 737-42
80. 80. Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119: 359-66
81. 81. Hancke E, Delescluse J, Plinck EPB, et al. The use of itraconazole in onychomycosis. Eur J Dermatol 1996; 6: 7-10
82. 82. Walsoc I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis: open and double-blind studies. Acta Derm Venereol (Stockh) 1990; 70: 137-40
83. 83. De Doncker P, Van Lint J, Docks P, et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995; 56: 180-3
84. 84. Bonifaz A, Carrasco-Gerard E, Saul A. Itraconazole in onychomycosis: intermittent dose schedule. Int J Dermatol 1997; 36: 70-2
85. 85. De Doncker P, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997; 37: 969-74
86. 86. Odom RB, Aly R, Scher RK, et al. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol 1997; 36: 231-5
87. 87. De Doncker P, Decroix J, Pierard GE, et al. Antifungal pulse therapy for onychomycosis. Arch Dermatol 1996; 132: 34-41
88. 88. Heikkilä H, Stubb S. Long-term results of patients with onychomycosis treated with itraconazole. Acta Derm Venereol (Stockh) 1997; 77: 70-1
89. 89. Havu V, Brandt H, Heikkilä H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toenail onychomycosis. Br J Dermatol 1997; 136: 230-4
90. 90. De Doncker P, Scher RK, Barah RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some non-dermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36: 173-7
91. 91. Bräutigam M, Nolting S, Schopf RE, et al. Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ 1995; 311: 919-22
92. 92. Tosti A, Piraccini BC, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595-600
93. 93. Honeyman JF, Talarico FS, Arruda LHF, et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis? J Eur Acad Dermatol Venereol 1997; 9: 215-21
94. 94. Arenas R, Dominguez-Cherit J. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995; 34: 138-43
95. 95. Evans EGV, Sigurgeirsson B, Billstein S. Continuous terbinafine versus intermittent itraconazole in the treatment of toenail onychomycosis (L.I.O.N. study). Focus on Fungal Infection 8; 1998 Mar 4-6; Orlando (FL)
96. 96. Scher RK. A placebo controlled, randomized, double-blind trial of once-weekly fluconazole (150, 300, or 45 mg) in the treatment of distal subungual onychomycosis of the toenail [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto, Canada, 380
97. 97. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3: 115-7
98. 98. Nahass GT, Sisto M. Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 1993; 186: 59-61
99. 99. Feuilhade M, Baran R, Goettmann S, et al. Onychomycoses dermatophytiques avec atteinte de la matrice: intérét de l'association d'un vernis contenant 5% d'amorolfine a un traitement oral par terbinafine. Ann Dermatol 1996; 123 Suppl.: 143
100. 100. Hann SK, Kim JB, Im S, et al. Itraconazole-induced acute hepatitis. Br J Dermatol 1993; 129: 500-1
101. 101. Rosen T. Debilitating edema associated with itraconazole therapy. Arch Dermatol 1994; 130: 260-1
102. 102. Heymann WR, Manders SM. Itraconazole-induced acute generalized exanthematic pustulosis. J Am Acad Dermatol 1995; 32: 131-2
103. 103. Zuckerman JM, Tunkel AR. Itraconazole: a new triazole antifungal agent. Infect Control Hosp Epidemiol 1994; 15: 397-410
104. 104. Tailor SAN, Gupta AK, Walker SE, et al. Peripheral edema due to nifedipine-itraconazole interaction: a case report. Arch Dermatol 1996; 132: 350-2
105. 105. Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. J Am Acad Dermatol 1995; 33: 134-5
106. 106. Rzany B, Mockenhaupt M, Gehring W, et al. Stevens-Johnson syndrome after terbinafine therapy. J Am Acad Dermatol 1994; 30: 509
107. 107. Carstens J, Wendelboe P, Sogaard H, et al. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol (Stockh) 1994; 74: 391-2
108. 108. McGregor JM, Rustin MHA. Terbinafine and erythema multiforme. Br J Dermatol 1994; 131: 587-8
109. 109. Inman W, Kubota K, Pearce G, et al. PEM Report Number 7. Itraconazole. Pharmacoepidemiol Drug Saf 1993; 2: 423-43
110. 110. O'Sullivan DP, Needham CA, Bangs A, et al. Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. Br J Clin Pharmacol 1996; 42: 559-65
111. 111. Shear NH, Gupta AK. Terbinafine for the treatment of pedal onychomycosis. Arch Dermatol 1995; 131: 937-42
112. 112. Bong JL, Lucke TW, Evans CD. Persistent impairment of taste resulting from terbinafine. Br J Dermatol 1998; 139: 747-8
113. 113. Gupta AK, Shear NH. Terbinafine: an update. J Am Acad Dermatol 1997; 37: 979-88
114. 114. Brodell RT, Elewski BE. Clinical pearl: systemic antifungal drugs and drug interactions. J Am Acad Dermatol 1995; 33: 259-60
115. 115. Robbins B, Chang CT, Cramer JA, et al. Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Clin Pharmacol Therapeutics 1996; 59: 275-83
116. 116. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993; S50-4
117. 117. Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol 1994; 31: S87-90
118. 118. Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmaco-economic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130 Suppl. 43: 35-44
119. 119. Davis R, Balfour JA. Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections. Pharmaco-Economics 1995; 8: 253-69
120. 120. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130 Suppl. 43: 32-4
121. 121. Bergman W, Rutten FFH. Orale behandling van onychomycose van de teennagels; vergelijking van kosteneffectiviteit van griseofulvin, itraconazole, ketoconazol en terbinafine. Ned Tijdschr Geneeskd 1994; 138: 2346-50
122. 122. Chren MM. Costs of therapy for dermatophyte infections. J Am Acad Dermatol 1994; 31: S103-6
123. 12.Van Doorslaer EKA, Tormans U, Gupta AK, et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology 1996; 193: 239-44
124. 124. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenail Pharmacoeconomics 1998; 13: 1-15
125. 125. Oh PI, Shear NH, Einarson TR. Cost-effectiveness analysis of antifungal therapy for onychomycosis. 1996 International Summit on Cutaneous Antifungal Therapy; 1996 May 26-28; Vancouver
126. 126. Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 1997; 19: 559-69
127. 127. Gupta AK, De Doncker P, Heenen M. An overview of assessment of the use of the antifungal agents itraconazole, terbinafine, and fluconazole in dermatology. In: Korting HC, Schäfer-Korting M, editors. The benefit/risk ratio. A handbook for the use of potentially hazardous drugs. Boca Raton (FL): CRC Press, 1999: 263-85